Kaynak: Proactive Investors Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Oxford Biomedica cuts 2026 revenue guidance as clients delay orders

Oxford Biomedica cuts 2026 revenue guidance as clients delay orders

Oxford BioMedica PLC (LSE:OXB), the cell and gene therapy manufacturer, has cut its revenue guidance for 2026 after clients deferred orders and a US site took longer than expected to come online. The company now expects full-year revenues of £180 million to £200 million.
İlgili Semboller 1
OXB OXB
Kaynak: Proactive Investors
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.